Novartis and existing investors GV, Kaiser Permanente Ventures and Roche Venture Fund helped the cancer test developer push its total funding past the $500m mark.
US-based oncology diagnostics technology developer Freenome completed a $270m series C round yesterday featuring pharmaceutical firms Roche and Novartis, healthcare provider Kaiser Permanente and internet and technology group Alphabet.
Bain Capital Life Sciences and Perceptive Advisors co-led the round, which included investment and financial services group Fidelity, American Cancer Society’s BrightEdge Ventures fund, Janus Henderson Investors, Farallon Capital Management and Rock Springs Capital.
Cormorant Asset Management, EcoR1 Capital, Catalio Capital Management, Colorectal Cancer Alliance, RA Capital Management, Sands Capital, Andreessen…
